GSK plc (GSK)
| Market Cap | 77.95B |
| Revenue (ttm) | 39.74B |
| Net Income (ttm) | 5.10B |
| Shares Out | 4.08B |
| EPS (ttm) | 1.24 |
| PE Ratio | 15.29 |
| Forward PE | 9.25 |
| Dividend | $1.54 (3.97%) |
| Ex-Dividend Date | Aug 16, 2024 |
| Volume | 6,479,900 |
| Open | 38.07 |
| Previous Close | 38.37 |
| Day's Range | 37.94 - 38.84 |
| 52-Week Range | 33.67 - 45.93 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 48.00 (+23.65%) |
| Earnings Date | Oct 30, 2024 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is $48.0, which is an increase of 23.65% from the latest price.
News
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin...
GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of ag...
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX.
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 y...
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer.
GSK's mRNA flu vaccine programme to proceed to late-stage trials
British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progres...
GSK's experimental HSV vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage t...
GSK's asthma drug Nucala meets main goal in smoker's lungs trial
British drugmaker GSK on Friday announced positive results from its late-stage trial of asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs.
GSK shares jump on win in Delaware court over ongoing Zantac battle
GSK shares jumped Wednesday on news Delaware's top court ruled in the pharmaceutical company's favor, by agreeing to review the admissibility of expert evidence that could play a part in the British f...
GSK's Q2 Success Amid Challenges: What Investors Need To Know
On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a mor...
BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
RICHMOND, Calif.--(BUSINESS WIRE)-- #aging--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the b...
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp...
GSK to seek dismissal of Florida case against heartburn drug Zantac
British drugmaker GSK said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
German panel endorses GSK, Pfizer RSV vaccines for elderly
Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection R...
Dividend Income: Lanny's July 2024 Summary
In July, we (my wife and I) received a dividend income total of $2,836.82. 2023 was up 24%. 7 months down in 2024 and the S&P 500 is still up almost 13%, despite the recent sell-offs. We have a high l...
GSK: Robust Financials, Strong Portfolio And Sector Rotation To Defensives Make It A Buy
GSK is a pharmaceutical company with key segments in specialty medicine, general medicine, and vaccines. Economic uncertainties arise from political forces, inflation rates and signs of a recession, m...
GSK wins latest trial over Zantac cancer claims
GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spoke...
India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand
India's GlaxoSmithKline Pharmaceuticals reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines.
GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter
UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year guidanc...
GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)
GSK's H1 2024 earnings report is strong, with healthy sales growth, solid core EPS increase, and upgraded outlook, resulting in attractive market multiples. However, the outlook still indicates that i...
GSK plc (GSK) Q2 2024 Earnings Call Transcript
GSK plc (NYSE:GSK) Q2 2024 Earnings Conference Call July 31, 2024 7:00 AM ET Company Participants Nick Stone - Head, IR Emma Walmsley - CEO Tony Wood - Chief Scientific Officer Luke Miels - Chief Com...
GSK Becomes Latest Pharma Firm To Lift Outlook
GSK (GSK) lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher.